Robert Zeiser, MD

Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.

Dr. Zeiser and Dr. Chao review ongoing clinical trials in the management of cGvHD – specifically the use of axatilimab and abatacept in SR/D cGvHD.

Experts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib.

Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.

Explore the primary treatment options for chronic Graft vs Host Disease (cGvHD) and delve into the challenges associated with prolonged steroid use, focusing on dosing strategies and adverse event management.

Two experts explore the essentials of Graft vs Host Disease (GvHD), understanding its symptoms, diagnosis, and distinguishing characteristics between acute and chronic forms.

Dr. Zeiser discusses the dynamic clinical evolution of Graft vs Host Disease (GvHD) in a concise overview, gaining insights into its progression and changing manifestations over time.

Closing out the program, Robert Zeiser, MD, shares what he is looking forward to in the field of graft-vs-host-disease.

Adverse events related to chronic graft-vs-host-disease therapies and strategies to manage these adverse effects are considered.

Robert Zeiser, MD, touches on additional therapeutic options for steroid-refractory chronic graft-vs-host-disease, such as extracorporeal photopheresis, mycophenolate, everolimus, and more.

Therapies for steroid-refractory chronic graft-vs-host disease, ibrutinib, ruxolitinib, and belumosudil, are explored in a comprehensive analysis.

A GVHD expert comments on the frontline therapy available for the condition.

Selection of prophylaxis regimen is reviewed followed by a discussion of the typical patient presentation of GVHD.

Dr Zeiser outlines the differences between acute and chronic GVHD and also reviews factors that put transplant patients at greater risk of GVHD.

Robert Zeiser, MD, reviews the pathophysiology of graft versus host disease and explains its relationship to the desired graft versus leukemia effect.

Robert Zeiser, MD, discusses the findings from the phase 3 REACH3 clinical trial of ruxolitinib as treatment of patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.